Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28898619 | 0.85 | THRB (0.33) | TSHR | |
| SCHEMBL27802209 | 0.79 | TLR8 (0.39) | TSHRMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3246397 | 0.75 | KDM4E (0.37) | TSHRMAPTBLMALDH1A1 | |
| SCHEMBL2456191 | 0.71 | — | — | |
| SCHEMBL6553858 | 0.71 | SMN1; SMN2 (0.42) | TSHRMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL578331 | 0.71 | MTNR1A (0.58) | MTNR1AMTNR1BMAPT | |
| SCHEMBL64412 | 0.71 | ALDH1A1 (0.34) | MAPTALDH1A1 | |
| SCHEMBL6856984 | 0.71 | CYP1A2 (0.37) | MAPT | |
| SCHEMBL2257677 | 0.71 | CYP1A2 (0.37) | MAPT | |
| SCHEMBL292920 | 0.71 | TLR8 (0.41) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | claimed |
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PNP, NANP, PHOSPHO1 | MTNR1A 4134/4885MTNR1B 4309/4885TSHR 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.